Header Logo

Connection

Theo Manschreck to Neuropsychological Tests

This is a "connection" page, showing publications Theo Manschreck has written about Neuropsychological Tests.
Connection Strength

0.781
  1. Manschreck TC, Chun J, Merrill AM, Maher BA, Boshes RA, Glatt SJ, Faraone SV, Tsuang MT, Seidman LJ. Impaired motor performance in adolescents at familial high-risk for schizophrenia. Schizophr Res. 2015 Oct; 168(1-2):44-9.
    View in: PubMed
    Score: 0.137
  2. Chan RC, McAlonan GM, Yang B, Lin L, Shum D, Manschreck TC. Prevalence of neurological soft signs and their neuropsychological correlates in typically developing Chinese children and Chinese children with ADHD. Dev Neuropsychol. 2010; 35(6):698-711.
    View in: PubMed
    Score: 0.093
  3. Manschreck TC, Maher BA, Candela SF, Redmond D, Yurgelun-Todd D, Tsuang M. Impaired verbal memory is associated with impaired motor performance in schizophrenia: relationship to brain structure. Schizophr Res. 2000 May 25; 43(1):21-32.
    View in: PubMed
    Score: 0.048
  4. Manschreck TC, Maher BA, Winzig L, Candela SF, Beaudette S, Boshes R. Age disorientation in schizophrenia: an indicator of progressive and severe psychopathology, not institutional isolation. J Neuropsychiatry Clin Neurosci. 2000; 12(3):350-8.
    View in: PubMed
    Score: 0.047
  5. Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci. 1999; 11(4):481-9.
    View in: PubMed
    Score: 0.043
  6. Manschreck TC, Maher BA, Beaudette SM, Redmond DA. Context memory in schizoaffective and schizophrenic disorders. Schizophr Res. 1997 Aug 29; 26(2-3):153-61.
    View in: PubMed
    Score: 0.040
  7. Blyler CR, Maher BA, Manschreck TC, Fenton WS. Line drawing as a possible measure of lateralized motor performance in schizophrenia. Schizophr Res. 1997 Jul 25; 26(1):15-23.
    View in: PubMed
    Score: 0.039
  8. Chun J, Peltier SJ, Yoon D, Manschreck TC, Deldin PJ. Prolongation of ERP latency and reaction time (RT) in simultaneous EEG/fMRI data acquisition. J Neurosci Methods. 2016 08 01; 268:78-86.
    View in: PubMed
    Score: 0.036
  9. Manschreck TC. Pathogenesis of delusions. Psychiatr Clin North Am. 1995 Jun; 18(2):213-29.
    View in: PubMed
    Score: 0.034
  10. Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. Ann Clin Psychiatry. 1994 Dec; 6(4):215-25.
    View in: PubMed
    Score: 0.033
  11. Chun J, Karam ZN, Marzinzik F, Kamali M, O'Donnell L, Tso IF, Manschreck TC, McInnis M, Deldin PJ. Can P300 distinguish among schizophrenia, schizoaffective and bipolar I disorders? An ERP study of response inhibition. Schizophr Res. 2013 Dec; 151(1-3):175-84.
    View in: PubMed
    Score: 0.030
  12. Thermenos HW, Whitfield-Gabrieli S, Seidman LJ, Kuperberg G, Juelich RJ, Divatia S, Riley C, Jabbar GA, Shenton ME, Kubicki M, Manschreck T, Keshavan MS, DeLisi LE. Altered language network activity in young people at familial high-risk for schizophrenia. Schizophr Res. 2013 Dec; 151(1-3):229-37.
    View in: PubMed
    Score: 0.030
  13. Scala S, Pousada A, Stone WS, Thermenos HW, Manschreck TC, Tsuang MT, Faraone SV, Seidman LJ. Verbal and visual-spatial memory impairment in youth at familial risk for schizophrenia or affective psychosis: a pilot study. Schizophr Res. 2013 Mar; 144(1-3):122-8.
    View in: PubMed
    Score: 0.029
  14. Manschreck TC, Schneyer ML, Weisstein CC, Laughery J, Rosenthal J, Celada T, Berner J. Freebase cocaine and memory. Compr Psychiatry. 1990 Jul-Aug; 31(4):369-75.
    View in: PubMed
    Score: 0.024
  15. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders. Biol Psychiatry. 1990 Jan 15; 27(2):150-8.
    View in: PubMed
    Score: 0.023
  16. Chan RC, Wang Y, Wang L, Chen EY, Manschreck TC, Li ZJ, Yu X, Gong QY. Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design. PLoS One. 2009 Dec 24; 4(12):e8469.
    View in: PubMed
    Score: 0.023
  17. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
    View in: PubMed
    Score: 0.019
  18. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006 Sep; 31(9):2033-46.
    View in: PubMed
    Score: 0.018
  19. Maher BA, Manschreck TC, Linnet J, Candela S. Quantitative assessment of the frequency of normal associations in the utterances of schizophrenia patients and healthy controls. Schizophr Res. 2005 Oct 15; 78(2-3):219-24.
    View in: PubMed
    Score: 0.017
  20. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.